Floatz logo

Antineoplaston As2-1

Merkel Cell Carcinoma

Phase 2Dormant
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
26/ 100
Competitive Position
81/ 100

Competitive context

46 Active assets in the Merkel Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3BB
Cyclophosphamide
Merck Sharp & Dohme LLC
Phase 2/3BB
Durvalumab
Ariceum Therapeutics GmbH
Phase 2B
Atezolizumab
Ariceum Therapeutics GmbH
Phase 2B
Nivolumab
Fred Hutchinson Cancer Center
Phase 2B

View all 50 →

Same molecule, other indications

Antineoplaston As2-1 is also rated in:

colon adenocarcinomaDormant
CC
Indicative ·
41 / 100
View asset →
colon carcinomaDormant
CC
Indicative ·
41 / 100
View asset →
mantle cell lymphomaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →